[1]
|
Chen, W., Zheng, R., Baade, P.D., Zhang, S., Zeng, H., Bray, F., et al. (2016) Cancer Statistics in China, 2015. CA: A Cancer Journal for Clinicians, 66, 115-132. https://doi.org/10.3322/caac.21338
|
[2]
|
Midha, A., Dearden, S. and McCormack, R. (2015) EGFR Mutation Incidence in Non-Small-Cell Lung Cancer of Adenocarcinoma Histology: A Systematic Review and Global Map by Ethnicity (mutMapII). American Journal of Cancer Research, 5, 2892-2911.
|
[3]
|
Oxnard, G.R., Lo, P.C., Nishino, M., Dahlberg, S.E., Lindeman, N.I., Butaney, M., et al. (2013) Natural History and Molecular Characteristics of Lung Cancers Harboring EGFR Exon 20 Insertions. Journal of Thoracic Oncology, 8, 179-184. https://doi.org/10.1097/JTO.0b013e3182779d18
|
[4]
|
Riess, J.W., Gandara, D.R., Frampton, G.M., Madison, R., Peled, N., Bufill, J.A., et al. (2018) Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. Journal of Thoracic Oncology, 13, 1560-1568. https://doi.org/10.1016/j.jtho.2018.06.019
|
[5]
|
Cardona, A.F., Rojas, L., Zatarain-Barrón, Z.L., Freitas, H.C., Granados, S.T., Castillo, O., et al. (2018) EGFR Exon 20 Insertion in Lung Adenocarcinomas among Hispanics (Geno1.2-CLICaP). Lung Cancer, 125, 265-272.
https://doi.org/10.1016/j.lungcan.2018.10.007
|
[6]
|
Arcila, M.E., Nafa, K., Chaft, J.E., Rekhtman, N., Lau, C., Reva, B.A., et al. (2013) EGFR Exon 20 Insertion Mutations in Lung Adenocarcinomas: Prevalence, Molecular Heterogeneity, and Clinicopathologic Characteristics. Molecular Cancer Therapeutics, 12, 220-229. https://doi.org/10.1158/1535-7163.MCT-12-0620
|
[7]
|
Yang, G., Li, J., Xu, H., Yang, Y., Yang, L., Xu, F., et al. (2020) EGFR Exon 20 Insertion Mutations in Chinese Advanced Non-Small Cell Lung Cancer Patients: Molecular Heterogeneity and Treatment Outcome from Nationwide Real-World Study. Lung Cancer, 145, 186-194. https://doi.org/10.1016/j.lungcan.2020.03.014
|
[8]
|
Leduc, C., Merlio, J.P., Besse, B., Blons, H., Debieuvre, D., Bringuier, P.P., et al. (2017) Clinical and molecular characteristics of non-small-cell lung cancer (NSCLC) harboring EGFR mutation: results of the nationwide French Cooperative Thoracic Intergroup (IFCT) Program. Annals of Oncology, 28, 2715-2724.
https://doi.org/10.1093/annonc/mdx404
|
[9]
|
Beau-Faller, M., Prim, N., Ruppert, A.-M., Nanni-Metéllus, I., Lacave, R., Lacroix, L., et al. (2014) Rare EGFR Exon 18 and Exon 20 Mutations in Non-Small-Cell Lung Cancer on 10117 Patients: A Multicentre Observational Study by the French ERMETIC-IFCT Network. Annals of Oncology, 25, 126-131. https://doi.org/10.1093/annonc/mdt418
|
[10]
|
Yasuda, H., Park, E., Yun, C.H., Sng, N.J., Lucena-Araujo, A.R., Yeo, W.L., et al. (2013) Structural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung Cancer. Science Translational Medicine, 5, Article No. 216ra177. https://doi.org/10.1126/scitranslmed.3007205
|
[11]
|
Yang, M., Xu, X., Cai, J., Ning, J., Wery, J.P. and Li, Q.-X. (2016) NSCLC Harboring EGFR Exon-20 Insertions after the Regulatory C-Helix of Kinase Domain Responds Poorly to Known EGFR Inhibitors. International Journal of Cancer, 139, 171-176. https://doi.org/10.1002/ijc.30047
|
[12]
|
Robichaux, J.P., Elamin, Y.Y., Tan, Z., Carter, B.W., Zhang, S., Liu, S., et al. (2018) Mechanisms and Clinical Activity of an EGFR and HER2 Exon 20-Selective Kinase Inhibitor in Non-Small Cell Lung Cancer. Nature Medicine, 24, 638-646. https://doi.org/10.1038/s41591-018-0007-9
|
[13]
|
Tu, H.Y., Ke, E.E., Yang, J.J., Sun, Y.L., Yan, H.H., Zheng, M.Y., et al. (2017) A Comprehensive Review of Uncommon EGFR Mutations in Patients with Non-Small Cell Lung Cancer. Lung Cancer, 114, 96-102.
https://doi.org/10.1016/j.lungcan.2017.11.005
|
[14]
|
Yang, J.C., Sequist, L.V., Geater, S.L., Tsai, C.M., Mok, T.S., Schuler, M., et al. (2015) Clinical Activity of Afatinib in Patients with Advanced Non-Small-Cell Lung Cancer Harbouring Uncommon EGFR Mutations: A Combined Post-Hoc Analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncology, 16, 830-838.
https://doi.org/10.1016/S1470-2045(15)00026-1
|
[15]
|
Kuiper, J.L., Hashemi, S.M.S., Thunnissen, E., Snijders, P.J., Grünberg, K., Bloemena, E., et al. (2016) Non-Classic EGFR Mutations in a Cohort of Dutch EGFR-Mutated NSCLC Patients and Outcomes Following EGFR-TKI Treatment. British Journal of Cancer, 115, 1504-1512. https://doi.org/10.1038/bjc.2016.372
|
[16]
|
Naidoo J, Sima CS, Rodriguez K, Busby, N., Nafa, K., Ladanyi, M., et al. (2015) Epidermal Growth Factor Receptor Exon 20 Insertions in Advanced Lung Adenocarcinomas: Clinical Outcomes and Response to Erlotinib. Cancer, 121, 3212-3220. https://doi.org/10.1002/cncr.29493
|
[17]
|
Wu, J.Y., Yu, C.J. and Shih, J.Y. (2019) Effectiveness of Treatments for Advanced Non-Small-Cell Lung Cancer with Exon 20 Insertion Epidermal Growth Factor Receptor Mutations. Clinical Lung Cancer, 20, e620-e630.
https://doi.org/10.1016/j.cllc.2019.06.018
|
[18]
|
Horn, L., Lin, H.M., Padda, S.K., Aggarwal, C., Elizabeth McCoach, C., Zhu, Y., et al. (2020) Indirect Comparison of TAK-788 VS. Real-World Data Outcomes In Refractory Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertions. Journal of Clinical Oncology, 38, 9580. https://doi.org/10.1200/JCO.2020.38.15_suppl.9580
|
[19]
|
Sabari, J.K., Shu, C.A., Park, K., Leighl, N., Mitchell, P., Kim, S., Lee, J., et al. (2021) Amivantamab in Post-Platinum EGFR Exon 20 Insertion Mutant Non-Small Cell Lung Cancer. Journal of Thoracic Oncology, 16, S108-S109.
https://doi.org/10.1016/j.jtho.2021.01.284
|